instruction:
In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.
question:
Glycyrrhetinic acid monoglucuronide (GAMG) is a great value-added and has considerable commercial interest due to its strong pharmacological activities and functional low-calorie sweetener. However GAMG is quite rare in natural plants, and it must be prepared from glycyrrhizin (GL) by hydrolysing one terminal glucuronic acid. β-Glucuronidase is the key enzyme in the biotransformation of GL to GAMG, but its activities need to be enhanced to facilitate the industrial large-scale production of GAMG. In this study, we identified that isoliquiritigenin (ISL), as one of chemical compositions from the total flavonoids glycyrrhiza (TFG), can significantly enhance β-glucuronidase activity in vitro. Measurements using high-performance liquid chromatography (HPLC) showed that the activity of β-glucuronidase could be increased by 2.66-fold via the addition of ISL to a β-glucuronidase solution that contained GL at a 3:10 molar ratio of ISL to GL. ISL was concluded to be an activator because ISL could reduce the K m and E a of β-glucuronidase reacting with GL. This study sheds new light on the mechanism of βglucuronidase and helps to make industrial production of GAMG through fermentation feasible. Published: xx xx xxxx OPEN www.nature.com/scientificreports/ 2 Scientific RepoRts | 7: 12503 |
answer:
Identification of isoliquiritigenin as an activator that stimulates the enzymatic production of glycyrrhetinic acid monoglucuronide OPEN


question:
We evaluated the acceptability of an additional ad hoc influenza vaccination among the health care professionals following seasons with significant antigenic drift. Self-administered, anonymous surveys were performed by hard copy questionnaires in public hospitals, and by an on-line platform available to all healthcare professionals, from April 1st to May 31st, 2015. A total of 1290 healthcare professionals completed the questionnaires, including doctors, nurses, and allied health professionals working in both the public and private systems. Only 31.8% of participating respondents expressed an intention to receive the additional vaccine, despite that the majority of them agreed or strongly agreed that it would bring benefit to the community (88.9%), save lives (86.7%), reduce medical expenses (76.3%), satisfy public expectation (82.8%), and increase awareness of vaccination (86.1%). However, a significant proportion expressed concern that the vaccine could disturb the normal immunization schedule (45.5%); felt uncertain what to do in the next vaccination round (66.0%); perceived that the summer peak might not occur (48.2%); and believed that the summer peak might not be of the same virus (83.5%). Furthermore, 27.8% of all respondents expected that the additional vaccination could weaken the efficacy of previous vaccinations; 51.3% was concerned about side effects; and 61.3% estimated that there would be a low uptake rate. If the supply of vaccine was limited, higher priority groups were considered to include the elderly aged !65 years with chronic medical conditions (89.2%), the elderly living in residential care homes (87.4%), and longstay residents of institutions for the disabled (80.7%). The strongest factors associated with accepting the additional vaccine included immunization with influenza vaccines in the past 3 years, higher perceived risk of contracting influenza, and higher perceived severity of the disease impact. The acceptability to an additional ad hoc influenza vaccination was low among healthcare professionals. This could have a negative impact on such additional vaccination campaigns since healthcare professionals are a key driver for vaccine acceptance. The discordance in perceived risk and acceptance of vaccination regarding self versus public deserves further evaluation. Abbreviations: AOR = adjusted odds ratios, WHO = world health organization. Editor: Barry Margulies. Ã x 2 test or Fisher exact tests for variables with any cell <5. Values are numbers (percentages) of respondents unless stated otherwise. The values in bold represented those with P < 0.10, which were selected as variables in the multivariate regression analysis.
answer:
Ad Hoc Influenza Vaccination During Years of Significant Antigenic Drift in a Tropical City With 2 Seasonal Peaks A Cross-Sectional Survey Among Health Care Practitioners


question:
Phenomenon of RNA-induced gene silencing is a highly conservative mechanism among eukaryotic organisms. Several classes of small RNAs (siRNAs and miRNAs) 21-25 nt in length, which play a significant role in the processes of development of an organism, occurred important components of antiviral defence in animals and plants. This review shortly describes the main stages of gene silencing mechanism, features of antiviral RNA silencing in plants, invertebrates, mammals, ways of suppression of RNA-interference by viruses, as well as possible approaches of utilization of abovementioned phenomenon for struggling against viral infections.
answer:

63 1 Abbreviations: PTGS-posttranscriptional gene silencing dsRNA-double stranded RNA nt-nucleotide siRNA-small interfering RNA miRNA-micro RNA RISC-RNA-induced silencing complex RdRP-RNA-dependent RNA polymerase TMV-tobacco mosaic virus VIGS-virus induced gene silencing CP-coat protein TEV-tobacco etch virus VSV-vesicular stomatitis virus PFV-1-primate foamy virus 1 GFP-green fluorescent protein EBV-Epstein-Barr virus PVY-potato virus Y PVX-potato virus X ORSV-Odontoglossum rings pot virus HIV-Human immunodeficiency virus HBV-Hepatitis B virus HCV-Hepatitis C virus SARS-CoV-Severe Acute Respiratory Syndrome- Coronavirus CMV-Cucumber mosaic virus ZYMV-Zucchini mosaic virus WMV-2-Watermelon mosaic virus-2 TSWV-Tomato wilt spot virus TCSV-Tomato chlorotic spot virus PRSV-Peanut ring spot virus Role of siRNAs and miRNAs in the Processes of RNA-Mediated Gene Silencing during Viral Infections 1